Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

IVES TRANSDERMAL ISOSORBIDE DINITRATE AGREEMENT WITH MOLECULON BIOTECH is aimed at providing Ives with marketing rights to new delivery form for the active ingredient in the Isordil line. A press release announcing the marketing arrangement noted that "the first stage of the agreement contemplates the development of a product as defined in the agreement." Following "necessary FDA approval," Moleculon would become the manufacturing company "on behalf of Ives. Ives has NDAs pending at FDA for several new uses and new dosage forms of Isordil. The company's NDAs are for use of the drug in congestive heart failure and for arterial spasm reduction after coronary bypass. In addition, the firm is trying to get FDA approval for three new dosage forms. With the Moleculon agreement, Ives joins at least one other firm, Marion, in the effort to develop a commercially successful isosorbide dinitrate product incorporating transdermal technology. Last April, Marion entered into a licensing agreement for a transdermal anti-anginal with two Japanese firms, Nitto Electric Industrial Company and Toa Eiyo. Marion's patch is in the early clinical testing stage. Under the terms of the Ives-Moleculon agreement, the marketing territory will be the U.S., its territories and possessions. The release points out that "Moleculon will be compensated by Ives pursuant to the agreement based upon Ives' commercial sales of the product."

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts